Bailey Jeffrey Allen 4

What Happened
Jeffrey Allen Bailey, a director of Aurinia Pharmaceuticals (AUPH), was granted 23,931 derivative awards (reported as an "A" — award) on June 4, 2026. The grant is reported at $0.00 at acquisition (no cash paid at grant); the filing identifies these as options that will vest one year from the grant date. This was a compensation award to a director, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-04 (reported on Form 4 filed 2026-06-08).
• Transaction type/code: A = Grant / Award (derivative).
• Quantity: 23,931 derivative awards; Price at grant reported as $0.00; reported value $0 at grant.
• Vesting: Per footnote, the options vest one year from the date of grant.
• Shares owned after transaction: Not specified in the provided Form 4 summary.
• Timeliness: Filed June 8, 2026; filing appears timely (within the required two business days).

Context
This was an option/award grant as part of director compensation—common for boards—and does not reflect an immediate purchase or sale. For derivative grants, watch future filings for vesting, option exercise details (including exercise price and potential sales), or subsequent Form 4s that show exercises or dispositions.